NCT06739330

Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 150 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.

Detailed description

One of the most common causes of chronic liver diseases worldwide is metabolic dysfunction-associated fatty liver disease (MAFLD), which affects about 30% of adults. Thyroid hormones are critical in maintaining metabolic homeostasis throughout life and are intimately linked to the liver. Dysfunctions of the thyroid gland have been implicated as one of the most important risk factors of MAFLD due to its important role in the hepatic synthesis of fatty acid and cholesterol. Maintaining liver metabolism requires thyroid function to be normal, while thyroid disorders may lead to liver disease progression.

Conditions

• Thyroid Dysfunction
• Metabolic Dysfunction-Associated Fatty Liver Disease

Interventions

Type	Name	Description
DEVICE	Fibroscan	Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.

Timeline

• Start date: 2024-12-19
• Primary completion: 2025-05-01
• Completion: 2025-05-01
• First posted: 2024-12-18
• Last updated: 2024-12-20

Locations

1 site across 1 country: Egypt